Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Obesity
 |
Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Obesity CME, CPE Rachel P. Rosovsky, MD, MPH and Stephan Moll, MD |
|
| Release Date: January 30, 2023 Expiration Date: January 30, 2024 |
||
|
In this activity, two experts discuss direct oral anticoagulants (DOACs) in patients with VTE and obesity and review updated guidelines. They will discuss safety and appropriate dosing strategies for patients with a certain BMI, as well as the use of prophylaxis. The program will conclude with a discussion on the use of DOACs in patients after bariatric surgery. Provided by MediCom Worldwide, Inc.This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. |
||
| Begin, Earn CreditView Only, No Credit | ||